Amgen (AMGN) has seen considerable action as demonstrated by a multitude of financial moves and market responses. On top of receiving
FDA approval for Uplizna for Generalized Myasthenia Gravis, it was granted orphan status for Blinatumomab for Leukaemia, increasing Amgen's portfolio of approved treatments. This development led to
Wells Fargo maintaining an equal-weight recommendation on stock and biotech stalwart
Jim Cramer endorsing the new drug based on its compelling data. Recent
price target adjustments by different firms show dynamic views on the company's value. Remarkably, the stock jumped by almost 16% in a month, indicating strong market confidence. Amgen is also expanding, revealing a $650M expansion of its U.S. manufacturing capabilities, creating hundreds of jobs and displaying its dedication to innovating in the biotech sphere. Despite these, AMGN also reported an expected decline in Q3 earnings. Yet, they beat those estimates, showing an earnings surge of 111% and raising 2025 guidance. As AMGN continues to show overall strong performance, multiple investors, including the Treasurer of North Carolina and Quantinno Capital Management, have increased their stakes significantly.
Amgen AMGN News Analytics from Tue, 15 Jul 2025 07:00:00 GMT to Sat, 13 Dec 2025 14:33:31 GMT -
Rating 8
- Innovation 5
- Information 8
- Rumor -4
